image
MDxHealth SA MDXH
Healthcare - Medical - Diagnostics & Research - NASDAQ - BE
Watchlist
$ 1.96
-1.51 %
$ 97 M
Market Cap
-1.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one MDXH stock under the worst case scenario is HIDDEN Compared to the current market price of 1.96 USD, MDxHealth SA is HIDDEN

MDXH Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one MDXH stock under the base case scenario is HIDDEN Compared to the current market price of 1.96 USD, MDxHealth SA is HIDDEN

MDXH Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one MDXH stock under the best case scenario is HIDDEN Compared to the current market price of 1.96 USD, MDxHealth SA is HIDDEN

MDXH Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart MDXH

image
1M -10%
6M -46%
1Y -89%
3Y -385%
5Y --%
All
FINANCIALS
70.2 M REVENUE
89.43%
Growth Rates
1Year 89.43%
3Years 56.33%
5Years 19.89%
7Years 12.98%
10Years 24.97%
-27.3 M OPERATING INCOME
27.90%
Growth Rates
1Year 27.90%
3Years -0.25%
5Years 3.17%
7Years -11.39%
10Years -5.45%
-43.1 M NET INCOME
-13.72%
Growth Rates
1Year -13.72%
3Years -16.69%
5Years -6.07%
7Years -18.88%
10Years -10.37%
-21.5 M OPERATING CASH FLOW
36.99%
Growth Rates
1Year 36.99%
3Years -2.02%
5Years 5.51%
7Years -3.78%
10Years -4.30%
-3.93 M INVESTING CASH FLOW
86.52%
Growth Rates
1Year 86.52%
3Years -94.17%
5Years -23.92%
7Years 4.22%
10Years -12.13%
32.3 M FINANCING CASH FLOW
54.89%
Growth Rates
1Year 54.89%
3Years 31.21%
5Years -4.98%
7Years 6.27%
10Years 2.89%
23.3 M REVENUE
5.23%
Growth Rates
1Year 89.43%
3Years 56.33%
5Years 19.89%
7Years 12.98%
10Years 24.97%
-6.09 M OPERATING INCOME
17.88%
Growth Rates
1Year 27.90%
3Years -0.25%
5Years 3.17%
7Years -11.39%
10Years -5.45%
-6.09 M NET INCOME
47.15%
Growth Rates
1Year -13.72%
3Years -16.69%
5Years -6.07%
7Years -18.88%
10Years -10.37%
-5.62 M OPERATING CASH FLOW
-31.35%
Growth Rates
1Year 36.99%
3Years -2.02%
5Years 5.51%
7Years -3.78%
10Years -4.30%
-13 K INVESTING CASH FLOW
98.32%
Growth Rates
1Year 86.52%
3Years -94.17%
5Years -23.92%
7Years 4.22%
10Years -12.13%
33.6 M FINANCING CASH FLOW
181.68%
Growth Rates
1Year 54.89%
3Years 31.21%
5Years -4.98%
7Years 6.27%
10Years 2.89%
Balance Sheet MDxHealth SA
image
Current Assets 38.2 M
Cash & Short-Term Investments 22.4 M
Receivables 11.3 M
Other Current Assets 4.51 M
Non-Current Assets 91 M
Long-Term Investments 763 K
PP&E 9.94 M
Other Non-Current Assets 80.3 M
Current Liabilities 19.5 M
Accounts Payable 8.81 M
Short-Term Debt 2.12 M
Other Current Liabilities 8.59 M
Non-Current Liabilities 102 M
Long-Term Debt 39.1 M
Other Non-Current Liabilities 63.3 M
EFFICIENCY
Earnings Waterfall MDxHealth SA
image
Revenue 70.2 M
Cost Of Revenue 26.3 M
Gross Profit 43.9 M
Operating Expenses 71.3 M
Operating Income -27.3 M
Other Expenses 15.8 M
Net Income -43.1 M
RATIOS
62.58% GROSS MARGIN
62.58%
Averages
1Year 62.58%
3Years 53.76%
5Years 40.55%
7Years 48.07%
10Years 50.69%
-38.93% OPERATING MARGIN
-38.93%
Averages
1Year -38.93%
3Years -87.30%
5Years -155.17%
7Years -131.34%
10Years -117.84%
-61.40% NET MARGIN
-61.40%
Averages
1Year -61.40%
3Years -111.90%
5Years -172.95%
7Years -144.23%
10Years -126.95%
-597.95% ROE
-597.95%
Averages
1Year -597.95%
3Years -400.86%
5Years -386.82%
7Years -289.23%
10Years -214.64%
-33.38% ROA
-33.38%
Averages
1Year -33.38%
3Years -38.88%
5Years -63.38%
7Years -55.35%
10Years -48.13%
-62.95% ROIC
-62.95%
Averages
1Year -62.95%
3Years -69.23%
5Years -100.55%
7Years -84.54%
10Years -71.24%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis MDxHealth SA
image
Net Income -43.1 M
Depreciation & Amortization 6.86 M
Capital Expenditures -5.02 M
Stock-Based Compensation 665 K
Change in Working Capital -2.12 M
Others 16.2 M
Free Cash Flow -26.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets MDxHealth SA
image
MDXH has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases.

image
-17.2 USD
INZY
Overvalued 1367.21%

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

image
-22.5 USD
DAWN
Overvalued 279.21%

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.

image
-9.05 USD
ABOS
Overvalued 648.61%

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant.

image
-10.8 USD
ELDN
Overvalued 368.81%

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States.

image
-15.8 USD
ELEV
Overvalued 2327.33%
6. Ownership
Insider Ownership MDxHealth SA
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Feb 03, 2023
Bought 4 M USD
MVM Partners, LLC
10 percent owner
+ 1000000
 4 USD
7. News
MDxHealth: Strong Buy On Its Cutting-Edge Urology Diagnostics MDxHealth SA offers a comprehensive portfolio of precision diagnostics targeting all stages of prostate cancer and advanced UTI detection, addressing a $4.9 billion TAM. The company's flagship products, ConfirmMDx (post-biopsy detection), SelectMDx (pre-biopsy screening), and GPS (treatment planning), are driving clinical adoption. MDxHealth achieved 21% YoY revenue growth in Q3 2024, with management forecasting positive EBITDA by 2025 through disciplined cash management and market penetration. seekingalpha.com - 1 month ago
MDxHealth to Participate in Piper Sandler Healthcare Conference MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the Piper Sandler 36th Annual Healthcare Conference, which will take place between Dec 3-5, 2024, in New York City. globenewswire.com - 1 month ago
MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript MDxHealth SA (NASDAQ:MDXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Michael K. McGarrity - Chief Executive Officer and Director Ron Kalfus - Chief Financial Officer Conference Call Participants Vidyun Bais - BTIG Thomas Flaten - Lake Street Capital Markets Jason Bednar - Piper Sandler Operator Good day, and welcome to the MDxHealth Third Quarter 2024 Earnings Call. seekingalpha.com - 2 months ago
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024 Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K. globenewswire.com - 2 months ago
MDxHealth Announces Pricing of Offering of Ordinary Shares MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value (“Ordinary Shares”) in a registered public offering (the “Offering”) at a price to the public of $2.00 per Ordinary Share for total gross proceeds of $40.0 million before deducting commissions and estimated offering expenses. A strategic partner is purchasing 1,500,000 Ordinary Shares in this Offering directly from the Company rather than through the underwriters. globenewswire.com - 3 months ago
MDxHealth Announces Launch of Offering of Ordinary Shares MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40.0 million of ordinary shares of the Company without nominal value ("Ordinary Shares") in a registered public offering (the “Offering”). The Company also expects to grant the underwriters a 30-day option to purchase up to 15% of the Ordinary Shares being offered, excluding any Ordinary Shares purchased directly from the Company in the Offering pursuant to any separate Securities Purchase Agreement. globenewswire.com - 3 months ago
MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript MDxHealth SA (NASDAQ:MDXH ) Q2 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Vidyun Bais - BTIG Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Operator Greetings, and welcome to the MDxHealth Second Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this call is being recorded. seekingalpha.com - 4 months ago
MDXH Stock Earnings: MDxHealth Misses EPS, Beats Revenue for Q2 2024 MDxHealth (NASDAQ: MDXH ) just reported results for the second quarter of 2024. MDxHealth reported earnings per share of -42 cents. investorplace.com - 4 months ago
MDxHealth Reports Q2 and Half Year 2024 Results MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 million Year-over-year H1 revenues increase by 34% to 42.0 million Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 21, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the second quarter and half year ended June 30, 2024. Michael K. globenewswire.com - 4 months ago
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the second quarter and six-month period ended June 30, 2024, after market close on Wednesday, August 21, 2024. Title: MDxHealth Presents Second Quarter and First Half 2024 Financial Results and Corporate Update Conference Call and Webcast Speakers: Michael K. globenewswire.com - 5 months ago
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary Q2 and half year 2024 revenues and cash. The Company expects to report Q2 and half year 2024 revenues of approximately $22.2 and $42.0 million, respectively, representing year-over-year growth of 32% and 34%, respectively, and representing sequential growth from Q1 of 12%. globenewswire.com - 6 months ago
Mdxhealth Appoints Sanford J. Siegel, M.D. Mdxhealth Appoints Sanford J. Siegel, M.D. globenewswire.com - 6 months ago
8. Profile Summary

MDxHealth SA MDXH

image
COUNTRY BE
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 97 M
Dividend Yield 0.00%
Description MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Contact CAP Business Center, Herstal, 4040 https://mdxhealth.com
IPO Date Nov. 4, 2021
Employees 300
Officers Mr. Ron Kalfus CPA Chief Financial Officer Mr. John A. Bellano Chief Commercial Officer Mr. Joseph Sollee J.D., LLM Executive Vice President of Corporate Development & General Counsel Mr. Michael K. McGarrity Chief Executive Officer & Executive Director Dr. Jason Poole Ph.D. Chief Scientific Officer Ms. Miriam Reyes Executive Vice President of Operations